Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted net loss per share of common stock attributable to NantHealth for the years ended December 31, 2021 and 2020:


	Year Ended December 31,
	2021		2020
Net loss per share numerator:
Net loss from continuing operations	$	(58,566)	$	(88,439)
Net loss attributable to noncontrolling interests	(284)		(120)
Net loss from continuing operations attributable to NantHealth	(58,282)		(88,319)
Income from discontinued operations, net of tax, attributable to NantHealth	23		31,993
Net loss for basic and diluted net loss per share	$	(58,259)	$	(56,326)


Weighted-average shares for basic net loss per share	114,148,604		110,954,858
Effect of dilutive securities	—		—
Weighted-average shares for dilutive net loss per share	114,148,604		110,954,858

Basic and diluted net loss per share attributable to NantHealth:
Continuing operations - common stock	$	(0.51)	$	(0.80)
Discontinued operations - common stock	$	—	$	0.29
Total net loss per share - common stock	$	(0.51)	$	(0.51)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following number of potential common shares at the end of each period were excluded from the calculation of diluted net loss per share attributable to common stockholders because their effect would have been anti-dilutive for the periods presented:


	Year Ended December 31,
	2021	2020


Unexercised stock options	14,475,636	10,025,124
Unvested restricted stock units	119,705	253,308
Convertible notes	35,732,853	8,815,655